{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:08:48Z","timestamp":1785247728443,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1607-24947"],"award-info":[{"award-number":["RG-1607-24947"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1607-24947"],"award-info":[{"award-number":["RG-1607-24947"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1607-24947"],"award-info":[{"award-number":["RG-1607-24947"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most multiple sclerosis (MS) patients given currently available disease-modifying drugs (DMDs) experience progressive disability. Accordingly, there is a need for new treatments that can limit the generation of new waves T cell autoreactivity that drive disease progression. Notably, immune cells express GABA<jats:sub>A<\/jats:sub>-receptors (GABA<jats:sub>A<\/jats:sub>-Rs) whose activation has anti-inflammatory effects such that GABA administration can ameliorate disease in models of type 1 diabetes, rheumatoid arthritis, and COVID-19. Here, we show that oral GABA, which cannot cross the blood\u2013brain barrier (BBB), does not affect the course of murine experimental autoimmune encephalomyelitis (EAE). In contrast, oral administration of the BBB-permeable GABA<jats:sub>A<\/jats:sub>-R-specific agonist homotaurine ameliorates monophasic EAE, as well as advanced-stage relapsing\u2013remitting EAE (RR-EAE). Homotaurine treatment beginning after the first peak of paralysis reduced the spreading of Th17 and Th1 responses from the priming immunogen to a new myelin T cell epitope within the CNS. Antigen-presenting cells (APC) isolated from homotaurine-treated mice displayed an attenuated ability to promote autoantigen-specific T cell proliferation. The ability of homotaurine treatment to limit epitope spreading within the CNS, along with its safety record, makes it an excellent candidate to help treat MS and other inflammatory disorders of the CNS.<\/jats:p>","DOI":"10.1038\/s41598-021-84751-3","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T11:03:05Z","timestamp":1615201385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis"],"prefix":"10.1038","volume":"11","author":[{"given":"Jide","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"84751_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0165-5728(98)00264-1","volume":"96","author":"J Tian","year":"1999","unstructured":"Tian, J., Chau, C., Hales, T. G. & Kaufman, D. L. GABA(A) receptors mediate inhibition of T cell responses. J. Neuroimmunol. 96, 21\u201328 (1999).","journal-title":"J. Neuroimmunol."},{"key":"84751_CR2","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.173.8.5298","volume":"173","author":"J Tian","year":"2004","unstructured":"Tian, J. et al. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J. Immunol. 173, 5298\u20135304 (2004).","journal-title":"J. Immunol."},{"key":"84751_CR3","doi-asserted-by":"publisher","first-page":"11692","DOI":"10.1073\/pnas.1102715108","volume":"108","author":"N Soltani","year":"2011","unstructured":"Soltani, N. et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc. Natl. Acad. Sci. U S A 108, 11692\u201311697. https:\/\/doi.org\/10.1073\/pnas.1102715108 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"84751_CR4","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.2337\/db13-1385","volume":"63","author":"J Tian","year":"2014","unstructured":"Tian, J., Dang, H., Nguyen, A. V., Chen, Z. & Kaufman, D. L. Combined therapy with GABA and proinsulin\/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting beta-cell replication in newly diabetic NOD mice. Diabetes 63, 3128\u20133134. https:\/\/doi.org\/10.2337\/db13-1385 (2014).","journal-title":"Diabetes"},{"key":"84751_CR5","doi-asserted-by":"publisher","first-page":"e25338","DOI":"10.1371\/journal.pone.0025338","volume":"6","author":"J Tian","year":"2011","unstructured":"Tian, J. et al. Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS ONE 6, e25338. https:\/\/doi.org\/10.1371\/journal.pone.0025338 (2011).","journal-title":"PLoS ONE"},{"key":"84751_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/08916934.2011.571223","volume":"44","author":"J Tian","year":"2011","unstructured":"Tian, J., Yong, J., Dang, H. & Kaufman, D. L. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 44, 465\u2013470 (2011).","journal-title":"Autoimmunity"},{"key":"84751_CR7","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1073\/pnas.0915139107","volume":"107","author":"R Bhat","year":"2010","unstructured":"Bhat, R. et al. Inhibitory role for GABA in autoimmune inflammation. Proc. Natl. Acad. Sci. U S A 107, 2580\u20132585 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"84751_CR8","doi-asserted-by":"publisher","first-page":"e17152","DOI":"10.1371\/journal.pone.0017152","volume":"6","author":"DW Wheeler","year":"2011","unstructured":"Wheeler, D. W. et al. Anaesthetic impairment of immune function is mediated via GABA(A) receptors. PLoS ONE 6, e17152. https:\/\/doi.org\/10.1371\/journal.pone.0017152 (2011).","journal-title":"PLoS ONE"},{"key":"84751_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/glia.21087","volume":"59","author":"M Lee","year":"2011","unstructured":"Lee, M., Schwab, C. & McGeer, P. L. Astrocytes are GABAergic cells that modulate microglial activity. Glia 59, 152\u2013165. https:\/\/doi.org\/10.1002\/glia.21087 (2011).","journal-title":"Glia"},{"key":"84751_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1471-4159.2012.07659.x","volume":"121","author":"EL Mead","year":"2012","unstructured":"Mead, E. L. et al. Microglial neurotransmitter receptors trigger superoxide production in microglia; consequences for microglial-neuronal interactions. J. Neurochem. 121, 287\u2013301. https:\/\/doi.org\/10.1111\/j.1471-4159.2012.07659.x (2012).","journal-title":"J. Neurochem."},{"key":"84751_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jneuroim.2007.05.013","volume":"188","author":"MG Reyes-Garcia","year":"2007","unstructured":"Reyes-Garcia, M. G., Hernandez-Hernandez, F., Hernandez-Tellez, B. & Garcia-Tamayo, F. GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6\/IL-12 production. J. Neuroimmunol. 188, 64\u201368 (2007).","journal-title":"J. Neuroimmunol."},{"key":"84751_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cellimm.2018.07.001","volume":"332","author":"L Januzi","year":"2018","unstructured":"Januzi, L. et al. Autocrine GABA signaling distinctively regulates phenotypic activation of mouse pulmonary macrophages. Cell Immunol. 332, 7\u201323. https:\/\/doi.org\/10.1016\/j.cellimm.2018.07.001 (2018).","journal-title":"Cell Immunol."},{"key":"84751_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/TP.0b013e31829c24be","volume":"96","author":"GJ Prud'homme","year":"2013","unstructured":"Prud\u2019homme, G. J. et al. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. Transplantation 96, 616\u2013623. https:\/\/doi.org\/10.1097\/TP.0b013e31829c24be (2013).","journal-title":"Transplantation"},{"key":"84751_CR14","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.molimm.2005.07.025","volume":"43","author":"S Alam","year":"2006","unstructured":"Alam, S., Laughton, D. L., Walding, A. & Wolstenholme, A. J. Human peripheral blood mononuclear cells express GABAA receptor subunits. Mol. Immunol. 43, 1432\u20131442 (2006).","journal-title":"Mol. Immunol."},{"key":"84751_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.molimm.2010.08.005","volume":"48","author":"SK Mendu","year":"2011","unstructured":"Mendu, S. K. et al. Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates. Mol. Immunol. 48, 399\u2013407. https:\/\/doi.org\/10.1016\/j.molimm.2010.08.005 (2011).","journal-title":"Mol. Immunol."},{"key":"84751_CR16","doi-asserted-by":"publisher","unstructured":"Tian, J., Milddleton, B. & Kaufman, D. L. GABA administration prevents severe illness and death following coronavirus infection in mice. bioRxiv, https:\/\/doi.org\/10.1101\/2020.10.04.325423 (2020).","DOI":"10.1101\/2020.10.04.325423"},{"key":"84751_CR17","doi-asserted-by":"publisher","first-page":"e42959","DOI":"10.1371\/journal.pone.0042959","volume":"7","author":"SK Mendu","year":"2012","unstructured":"Mendu, S. K., Bhandage, A., Jin, Z. & Birnir, B. Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes. PLoS ONE 7, e42959 (2012).","journal-title":"PLoS ONE"},{"key":"84751_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ebiom.2018.03.019","volume":"30","author":"AK Bhandage","year":"2018","unstructured":"Bhandage, A. K. et al. GABA regulates release of inflammatory cytokines from peripheral blood mononuclear cells and CD4(+) T cells and is immunosuppressive in type 1 diabetes. EBioMedicine 30, 283\u2013294. https:\/\/doi.org\/10.1016\/j.ebiom.2018.03.019 (2018).","journal-title":"EBioMedicine"},{"issue":"Suppl 1","key":"84751_CR19","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1111\/j.1526-4610.2005.4501006.x","volume":"45","author":"HS White","year":"2005","unstructured":"White, H. S. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. Headache 45(Suppl 1), S48-56. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.4501006.x (2005).","journal-title":"Headache"},{"key":"84751_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/B978-0-444-52899-5.00021-6","volume":"108","author":"RJ Porter","year":"2012","unstructured":"Porter, R. J., Dhir, A., Macdonald, R. L. & Rogawski, M. A. Mechanisms of action of antiseizure drugs. Handb. Clin. Neurol. 108, 663\u2013681. https:\/\/doi.org\/10.1016\/B978-0-444-52899-5.00021-6 (2012).","journal-title":"Handb. Clin. Neurol."},{"key":"84751_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1358\/dot.2006.42.5.973584","volume":"42","author":"TM Wright","year":"2006","unstructured":"Wright, T. M. Tramiprosate. Drugs Today (Barc) 42, 291\u2013298 (2006).","journal-title":"Drugs Today (Barc)"},{"key":"84751_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais, F. et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28, 537\u2013547 (2007).","journal-title":"Neurobiol. Aging"},{"key":"84751_CR23","first-page":"102","volume":"7","author":"PS Aisen","year":"2010","unstructured":"Aisen, P. S. et al. Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - A randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci. 7, 102\u2013111 (2010).","journal-title":"Arch. Med. Sci."},{"key":"84751_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"S Gauthier","year":"2009","unstructured":"Gauthier, S. et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: Exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550\u2013557 (2009).","journal-title":"J. Nutr. Health Aging"},{"key":"84751_CR25","unstructured":"Tsolaki, M. Future strategies of management of Alzheimer's disease. The role of homotaurine. Hell J. Nucl. Med. 22 Suppl, 82\u201394 (2019)."},{"key":"84751_CR26","doi-asserted-by":"publisher","first-page":"16555","DOI":"10.1038\/s41598-018-32733-3","volume":"8","author":"J Tian","year":"2018","unstructured":"Tian, J., Dang, H., Wallner, M., Olsen, R. & Kaufman, D. L. Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Sci. Rep. 8, 16555. https:\/\/doi.org\/10.1038\/s41598-018-32733-3 (2018).","journal-title":"Sci. Rep."},{"key":"84751_CR27","doi-asserted-by":"publisher","unstructured":"Tian, J. et al. Homotaurine treatment enhances CD4+ and CD8+ Treg responses and synergizes with low-dose anti-CD3 to enhance diabetes remission in type 1 diabetic mice. ImmuoHorizons 23(10), 498\u2013510, https:\/\/doi.org\/10.4049\/immunohorizons.1900019 (2019).","DOI":"10.4049\/immunohorizons.1900019"},{"key":"84751_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1084\/jem.182.1.75","volume":"182","author":"BL McRae","year":"1995","unstructured":"McRae, B. L., Vanderlugt, C. L., Dal Canto, M. C. & Miller, S. D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182, 75\u201385 (1995).","journal-title":"J. Exp. Med."},{"key":"84751_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4049\/jimmunol.164.2.670","volume":"164","author":"CL Vanderlugt","year":"2000","unstructured":"Vanderlugt, C. L. et al. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 164, 670\u2013678 (2000).","journal-title":"J. Immunol."},{"key":"84751_CR30","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.4049\/jimmunol.166.7.4757","volume":"166","author":"OS Targoni","year":"2001","unstructured":"Targoni, O. S. et al. Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the course of experimental allergic encephalomyelitis. J. Immunol. 166, 4757\u20134764 (2001).","journal-title":"J. Immunol."},{"key":"84751_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clim.2010.09.004","volume":"137","author":"S Kuerten","year":"2010","unstructured":"Kuerten, S. et al. The clinical course of EAE is reflected by the dynamics of the neuroantigen-specific T cell compartment in the blood. Clin. Immunol. 137, 422\u2013432. https:\/\/doi.org\/10.1016\/j.clim.2010.09.004 (2010).","journal-title":"Clin. Immunol."},{"key":"84751_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nm1202","volume":"11","author":"EJ McMahon","year":"2005","unstructured":"McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H. & Miller, S. D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11, 335\u2013339 (2005).","journal-title":"Nat. Med."},{"key":"84751_CR33","doi-asserted-by":"publisher","first-page":"e25337","DOI":"10.1371\/journal.pone.0025337","volume":"6","author":"J Tian","year":"2011","unstructured":"Tian, J., Dang, H. & Kaufman, D. L. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ss-cells in diabetic NOD mice. PLoS ONE 6, e25337. https:\/\/doi.org\/10.1371\/journal.pone.0025337 (2011).","journal-title":"PLoS ONE"},{"key":"84751_CR34","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/jcp.24884","volume":"230","author":"S Huang","year":"2015","unstructured":"Huang, S., Mao, J., Wei, B. & Pei, G. The anti-spasticity drug baclofen alleviates collagen-induced arthritis and regulates dendritic cells. J. Cell Physiol. 230, 1438\u20131447. https:\/\/doi.org\/10.1002\/jcp.24884 (2015).","journal-title":"J. Cell Physiol."},{"key":"84751_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1600-0625.2010.01076.x","volume":"19","author":"B Duthey","year":"2010","unstructured":"Duthey, B. et al. Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp. Dermatol. 19, 661\u2013666. https:\/\/doi.org\/10.1111\/j.1600-0625.2010.01076.x (2010).","journal-title":"Exp. Dermatol."},{"key":"84751_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00581047","volume":"32","author":"PE Beales","year":"1995","unstructured":"Beales, P. E. et al. Baclofen, a gamma-aminobutyric acid-b receptor agonist, delays diabetes onset in the non-obese diabetic mouse. Acta Diabetol. 32, 53\u201356 (1995).","journal-title":"Acta Diabetol."},{"key":"84751_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fncel.2015.00284","volume":"9","author":"T Crowley","year":"2015","unstructured":"Crowley, T. et al. Modulation of TLR3\/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: Relevance to therapeutic effects in multiple sclerosis. Front. Cell Neurosci. 9, 284. https:\/\/doi.org\/10.3389\/fncel.2015.00284 (2015).","journal-title":"Front. Cell Neurosci."},{"key":"84751_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/71555","volume":"6","author":"D Pitt","year":"2000","unstructured":"Pitt, D., Werner, P. & Raine, C. S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6, 67\u201370. https:\/\/doi.org\/10.1038\/71555 (2000).","journal-title":"Nat. Med."},{"key":"84751_CR39","doi-asserted-by":"publisher","first-page":"186068","DOI":"10.1155\/2013\/186068","volume":"2013","author":"G Sulkowski","year":"2013","unstructured":"Sulkowski, G., Dabrowska-Bouta, B. & Struzynska, L. Modulation of neurological deficits and expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors. Biomed. Res. Int. 2013, 186068. https:\/\/doi.org\/10.1155\/2013\/186068 (2013).","journal-title":"Biomed. Res. Int."},{"key":"84751_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1515\/revneuro-2012-0062","volume":"24","author":"M Kostic","year":"2013","unstructured":"Kostic, M., Zivkovic, N. & Stojanovic, I. Multiple sclerosis and glutamate excitotoxicity. Rev. Neurosci. 24, 71\u201388. https:\/\/doi.org\/10.1515\/revneuro-2012-0062 (2013).","journal-title":"Rev. Neurosci."},{"key":"84751_CR41","doi-asserted-by":"publisher","first-page":"e113954","DOI":"10.1371\/journal.pone.0113954","volume":"9","author":"G Sulkowski","year":"2014","unstructured":"Sulkowski, G., Dabrowska-Bouta, B., Salinska, E. & Struzynska, L. Modulation of glutamate transport and receptor binding by glutamate receptor antagonists in EAE rat brain. PLoS ONE 9, e113954. https:\/\/doi.org\/10.1371\/journal.pone.0113954 (2014).","journal-title":"PLoS ONE"},{"key":"84751_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.neuroscience.2011.08.076","volume":"199","author":"MJ Bibolini","year":"2011","unstructured":"Bibolini, M. J. et al. Inhibitory role of diazepam on autoimmune inflammation in rats with experimental autoimmune encephalomyelitis. Neuroscience 199, 421\u2013428. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.08.076 (2011).","journal-title":"Neuroscience"},{"key":"84751_CR43","doi-asserted-by":"publisher","unstructured":"Fernandez Hurst, N. et al. Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 313, 145\u2013151, https:\/\/doi.org\/10.1016\/j.jneuroim.2017.09.012 (2017).","DOI":"10.1016\/j.jneuroim.2017.09.012"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84751-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84751-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84751-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:57:29Z","timestamp":1670043449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84751-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84751"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84751-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DLK. and JT. are inventors of GABA and GABA-R related patents. MS has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5402"}}